Key result
Metabolic syndrome exacerbates chronic lung disease severity through systemic inflammation and insulin resistance.
Why the study?
Metabolic syndrome clusters insulin resistance, obesity, dyslipidaemia, and hypertension to elevate cardiovascular and diabetes risk and significantly impacts patients with lung diseases such as COPD, asthma, and interstitial lung disease.
This narrative review highlights the pathophysiological links—such as systemic inflammation, oxidative stress, and insulin resistance—between metabolic syndrome and chronic lung diseases, emphasizing the need for a multidisciplinary management strategy combining lifestyle modifications and targeted pharmacotherapy to reduce cardiometabolic and pulmonary morbidity.
Answers are grounded in this paper and cite their sources.
May inform integrated cardiometabolic-respiratory assessment; leaves open validation of multidisciplinary strategies in prospective trials.
Metabolic syndrome is a complex disorder characterized by a cluster of conditions, including insulin resistance, obesity, dyslipidaemia, and hypertension, which collectively elevate the risk of cardiovascular disease and type 2 diabetes mellitus and its significant impact on patients with lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung disease (ILD). This review explores the pathophysiology of Metbolic Syndrome, emphasizing the roles of insulin resistance, chronic inflammation, the complex interplay between MetS and lung diseases, focusing on systemic inflammation, oxidative stress, and immune system activation in its development. These factors exacerbate pulmonary symptoms and contribute to multi-organ complications, including cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), and cognitive decline. Clinical implications are discussed, highlighting the increased risks of cardiovascular disease, cognitive impairment, and frailty, particularly in older adults and specific gender groups. Management strategies, such as lifestyle interventions, pharmacological treatments, and novel therapeutic approaches like sacubitril/valsartan and telmisartan, are reviewed to underscore the importance of early intervention. This review also highlights the importance of a multidisciplinary approach to management, integrating lifestyle modifications, pharmacological interventions (e.g., statins, GLP-1 agonists), and emerging therapies (e.g., senolytics, gut-lung axis modulation). The paper concludes with a call for targeted therapies to address the underlying mechanisms of Metabolic Syndrome in high-risk populations and by addressing pulmonary components, such strategies aim to improve patient outcomes and reduce morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) conducted a review in Metabolic syndrome and chronic lung diseases (COPD, asthma, interstitial lung disease). Metabolic syndrome was evaluated. Metabolic syndrome exacerbates chronic lung diseases like COPD, asthma, and ILD via systemic inflammation, oxidative stress, and insulin resistance, requiring multidisciplinary management.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: